

Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Global Forecast to 2029

Market Report | 2024-04-24 | 402 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The vaccines market (including COVID-19 vaccines) is projected to reach USD 94.9 Billion by 2029 from USD 78.0 Billion in 2024, at a CAGR of 4.0% during the forecast period. Similarly the vaccines market (excluding COVID-19 vaccines) is projected to reach USD 80.3 Billion by 2029 from USD 53.0 Billion in 2024, at a CAGR of 8.7% during the forecast period. The vaccines market is driven by several key factors, including increasing global population, rising prevalence of infectious diseases, and growing awareness of preventive healthcare. Technological advancements in vaccine development, coupled with expanding immunization programs worldwide, contribute to market growth.

"The conjugate vaccines segment (excluding COVID -19 vaccines) held the dominant share in the vaccines market."

Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, conjugate vaccines and other vaccines. Conjugate vaccines segment dominated the vaccine market in 2023. Robust research and development investments, strategic partnerships, and favorable regulatory environments have further bolstered the prominence of conjugated vaccines, solidifying their position as indispensable tools in the fight against infectious diseases and driving sustained growth in the vaccines market.

"HPV segment (excluding COVID-19 vaccines) accounted for the largest share of the disease indication segment in 2023."

Based on disease indication, the vaccines market (excluding COVID-19 vaccines) is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, RSV, and other disease indications. In 2023, HPV segment dominated the vaccines market. RSV segment is anticipated to grow at

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

significant CAGR during the forecast period of 2024-2028 owing to various factors such as launch of new HPV vaccine and robust products under clinical trials.

"Asia Pacific region is likely to grow at a faster pace in the vaccines market (excluding COVID -19 vaccines)."

The vaccines market (excluding COVID-19 vaccines) region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. The Asia-Pacific region is poised to experience significant growth in the vaccines market due to several key factors such as increasing healthcare expenditure in countries like China, India, and Southeast Asian nations are driving demand for vaccines to combat infectious diseases. Expanding government initiatives aimed at improving vaccination coverage and healthcare infrastructure further stimulate market growth.

The primary interviews conducted for this report can be categorized as follows:

-By Respondent: Supply Side- 80%, and Demand Side - 20%

-By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%

-By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East-4% and Africa -1%

List of Companies Profiled in the Report:

-GSK plc (UK)

-Merck & Co., Inc. (US)

-Pfizer, Inc. (US)

-Sanofi (France)

-CSL (Australia)

-Emergent (US)

-Johnson & Johnson Services Inc. (US)

-AstraZeneca (UK)

-Serum Institute of India Pvt. Ltd. (India)

-Bavarian Nordic (Denmark)

-Mitsubishi Tanabe Pharma Corporation (Japan)

-Daiichi Sankyo Company, Limited (Japan)

-Panacea Biotec (India)

-Biological E. Limited (India)

-Bharat Biotech (India)

-Novavax (US)

-Inovio Pharmaceuticals (US)

-Sinovac (China)

-Incepta Pharmaceuticals (Bangladesh)

-Valneva SE (France),

-VBI Vaccines Inc. (US)

-Bio Farma (Indonesia)

-FSUE NPO Microgen (Russia)

-Zhi fei Biological (China)

-Indian Immunologicals Ltd (India)

Research Coverage:

This report provides a detailed picture of the vaccine market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, government support and funding for vaccine development), restraints (High cost of vaccine development), opportunities (Rising focus on therapeutic vaccines, Extensive R&D for vaccines and increased investments in clinical trials) and challenges (stringent regulatory processes, product recall) are influencing the growth of vaccines market.
- Product Development/Innovation: Detailed insights on newly launched products of the vaccines market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the vaccines market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the vaccines market.
- Pipeline Analysis: Comprehensive information about products under clinical trials.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark).

Table of Contents:

1□INTRODUCTION□	51
1.1□STUDY OBJECTIVES□	51
1.2□MARKET DEFINITION□	51
1.2.1□INCLUSIONS AND EXCLUSIONS□	52
1.3□MARKET SCOPE□	53
1.3.1□MARKETS COVERED□	53
1.3.2□REGIONS COVERED□	53
1.3.3□YEARS CONSIDERED□	54
1.3.4□CURRENCY CONSIDERED□	54
1.4□STAKEHOLDERS□	54
1.5□SUMMARY OF CHANGES□	55
1.5.1□RECESSION IMPACT□	55
2□RESEARCH METHODOLOGY□	56
2.1□RESEARCH DATA□	56
2.2□RESEARCH APPROACH□	56
FIGURE 1□RESEARCH DESIGN□	56
2.2.1□SECONDARY DATA□	57
2.2.2□PRIMARY DATA□	58
FIGURE 2□BREAKDOWN OF PRIMARIES□	58
2.2.2.1□Primary research□	58
2.3□MARKET SIZE ESTIMATION□	59
FIGURE 3□MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023□	59
FIGURE 4□MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023□	60
FIGURE 5□ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS, 2023□	60
2.3.1□INSIGHTS FROM PRIMARIES□	62

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 6	MARKET VALIDATION FROM PRIMARY EXPERTS	62
2.3.2	SEGMENTAL ASSESSMENT	62
FIGURE 7	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	62
2.4	GROWTH RATE ASSUMPTIONS	64
FIGURE 8	VACCINES MARKET: CAGR PROJECTION (2024-2029)	64
FIGURE 9	VACCINES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES	65
2.5	MARKET BREAKDOWN AND DATA TRIANGULATION	66
FIGURE 10	DATA TRIANGULATION METHODOLOGY	66
2.6	STUDY ASSUMPTIONS	67
2.7	RESEARCH LIMITATIONS	67
2.8	RISK ASSESSMENT	67
2.9	RECESSION IMPACT ANALYSIS	68
3	EXECUTIVE SUMMARY	69
FIGURE 11	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)	69
FIGURE 12	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)	70
FIGURE 13	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION)	71
FIGURE 14	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2024 VS. 2029 (USD MILLION)	72
FIGURE 15	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION)	73
FIGURE 16	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024 VS. 2029 (USD MILLION)	74
FIGURE 17	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)	75
FIGURE 18	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION)	76
FIGURE 19	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION)	77
FIGURE 20	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY END USER, 2024 VS. 2029 (USD MILLION)	78
FIGURE 21	GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (EXCLUDING COVID-19 VACCINES)	79
FIGURE 22	GEOGRAPHICAL SNAPSHOT OF VACCINES MARKET (INCLUDING COVID-19 VACCINES)	80
4	PREMIUM INSIGHTS	81
4.1	VACCINES MARKET OVERVIEW (INCLUDING COVID-19 VACCINES)	81
FIGURE 23	RIISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET	81
4.2	VACCINES MARKET OVERVIEW (EXCLUDING COVID-19 VACCINES)	82
FIGURE 24	LAUNCH OF RSV VACCINES AND STRONG PRODUCT PIPELINE TO DRIVE MARKET	82
4.3	NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY AND COUNTRY, 2023	83
FIGURE 25	US AND CONJUGATE VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN VACCINES MARKET IN 2023	83
4.4	GEOGRAPHICAL GROWTH OPPORTUNITIES: VACCINES MARKET (EXCLUDING COVID-19 VACCINES)	84
FIGURE 26	ASIA PACIFIC MARKETS TO REGISTER HIGHEST GROWTH RATES DURING FORECAST PERIOD	84
5	MARKET OVERVIEW	85
5.1	INTRODUCTION	85
5.2	MARKET DYNAMICS	85
FIGURE 27	DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: VACCINES MARKET	85
TABLE 1	IMPACT ANALYSIS: VACCINES MARKET	86
5.2.1	DRIVERS	86
5.2.1.1	Focus on vaccine development and launches	86
5.2.1.2	Rising prevalence of infectious diseases	87
FIGURE 28	US: INCIDENCE OF TUBERCULOSIS, 2017-2021	88
5.2.1.3	Increasing immunization programs	88
5.2.1.4	Advancements in vaccine technology	89
5.2.1.5	Government support and funding for vaccine development	89
TABLE 2	NIH FUNDING FOR VACCINE RESEARCH, 2020-2024 (USD MILLION)	90

5.2.2	RESTRAINTS	90
5.2.2.1	High cost of vaccine development	90
5.2.3	OPPORTUNITIES	91
5.2.3.1	Rising focus on therapeutic vaccines	91
5.2.3.2	Extensive R&D for vaccines and increased investments in clinical trials	91
5.2.4	CHALLENGES	92
5.2.4.1	Stringent regulatory processes	92
5.2.4.2	Product recalls	92
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	93
FIGURE 29		REVENUE SHIFTS AND NEW REVENUE POCKETS FOR VACCINE PROVIDERS
5.4	PRICING ANALYSIS	93
5.4.1	AVERAGE SELLING PRICE OF PRODUCTS, BY KEY PLAYER	93
TABLE 3		AVERAGE SELLING PRICE OF PEDIATRIC VACCINES
TABLE 4		AVERAGE SELLING PRICE OF ADULT VACCINES
5.4.2	AVERAGE SELLING PRICE, BY PRODUCT TYPE	96
TABLE 5		AVERAGE SELLING PRICE OF CONJUGATE VACCINES
TABLE 6		AVERAGE SELLING PRICE OF RECOMBINANT VACCINES
TABLE 7		AVERAGE SELLING PRICE OF INACTIVATED & SUBUNIT VACCINES
TABLE 8		AVERAGE SELLING PRICE OF LIVE ATTENUATED VACCINES
TABLE 9		AVERAGE SELLING PRICE OF TOXOID VACCINES
TABLE 10		AVERAGE SELLING PRICE OF M-RNA VACCINES
5.4.3	AVERAGE SELLING PRICE TREND	99
5.5	TECHNOLOGY ANALYSIS	99
5.5.1	MRNA VACCINES	99
5.5.2	DNA TECHNOLOGY	99
5.5.3	VLP VACCINE TECHNOLOGY	99
5.6	VALUE CHAIN ANALYSIS	100
FIGURE 30		VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES TO CONTRIBUTE MAXIMUM VALUE
5.7	PIPELINE ANALYSIS	101
FIGURE 31		VACCINES MARKET: CLINICAL TRIALS, BY PHASE
FIGURE 32		VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION
TABLE 11		PIPELINE PRODUCTS UNDER PHASE 2 AND PHASE 3 CLINICAL TRIALS
TABLE 12		VACCINE PIPELINE PRODUCTS UNDER PHASE-3 CLINICAL TRIALS FOR RSV
5.7.1	KEY PIPELINE PRODUCTS	112
TABLE 13		KEY PIPELINE VACCINES: GSK PLC
TABLE 14		KEY PIPELINE VACCINES: MERCK & CO., INC.
TABLE 15		KEY PIPELINE VACCINES: PFIZER INC.
TABLE 16		KEY PIPELINE VACCINES: SANOFI S.A.
5.8	ECOSYSTEM/MARKET MAP	113
FIGURE 33		ECOSYSTEM/MARKET MAP
TABLE 17		ROLE IN ECOSYSTEM: VACCINES MARKET
5.9	REGULATORY ANALYSIS	114
TABLE 18		NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19		EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20		ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21		LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22		MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 23	AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	118
5.10	PORTER'S FIVE FORCES ANALYSIS	118
TABLE 24	PORTER'S FIVE FORCES ANALYSIS	118
5.10.1	THREAT OF NEW ENTRANTS	119
5.10.2	THREAT OF SUBSTITUTES	119
5.10.3	BARGAINING POWER OF SUPPLIERS	119
5.10.4	BARGAINING POWER OF BUYERS	119
5.10.5	INTENSITY OF COMPETITIVE RIVALRY	119
5.11	PATENT ANALYSIS	120
FIGURE 34	PATENT APPLICATIONS FOR VACCINES, SEPTEMBER 2013-SEPTEMBER 2023	120
TABLE 25	VACCINES MARKET: INDICATIVE LIST OF PATENTS	121
5.12	KEY CONFERENCES & EVENTS, 2024-2025	122
TABLE 26	DETAILED LIST OF CONFERENCES & EVENTS	122
5.13	KEY STAKEHOLDERS & BUYING CRITERIA	123
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	123
FIGURE 35	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES	123
5.13.2	KEY BUYING CRITERIA	123
FIGURE 36	KEY BUYING CRITERIA FOR END USERS	123
6	VACCINES MARKET, BY TECHNOLOGY	124
6.1	INTRODUCTION	125
TABLE 27	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)	125
TABLE 28	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION)	126
6.2	CONJUGATE VACCINES	126
6.2.1	INCREASING PUBLIC-PRIVATE PARTNERSHIPS TO DRIVE MARKET	126
TABLE 29	CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	127
TABLE 30	NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	128
TABLE 31	EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	128
TABLE 32	ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	129
TABLE 33	LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	129
6.3	RECOMBINANT VACCINES	130
6.3.1	LOW POST-VACCINATION REACTIONS AND REDUCED NEED FOR BOOSTER DOSES TO DRIVE MARKET	130
TABLE 34	EXAMPLES OF RECOMBINANT VACCINES	130
TABLE 35	RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	131
TABLE 36	NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	131
TABLE 37	EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	132
TABLE 38	ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	132
TABLE 39	LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	133
6.4	INACTIVATED & SUBUNIT VACCINES	133
6.4.1	EASE OF STORAGE AND TRANSPORTATION TO SUPPORT GROWTH	133
TABLE 40	EXAMPLES OF INACTIVATED & SUBUNIT VACCINES	134

TABLE 41	INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	135
TABLE 42	NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	135
TABLE 43	EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	136
TABLE 44	ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	136
TABLE 45	LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	137
6.5	LIVE ATTENUATED VACCINES	137
6.5.1	HIGH COST OF STORAGE AND LIMITED FINANCIAL RESOURCES OF DISTRIBUTORS TO RESTRAIN MARKET	137
TABLE 46	EXAMPLES OF LIVE ATTENUATED VACCINES	138
TABLE 47	LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	138
TABLE 48	NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	139
TABLE 49	EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	139
TABLE 50	ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	140
TABLE 51	LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	140
6.6	TOXOID VACCINES	141
6.6.1	RISING PREVALENCE OF BACTERIAL INFECTIONS AMONG INFANTS AND CHILDREN TO DRIVE MARKET	141
TABLE 52	EXAMPLES OF TOXOID VACCINES	141
TABLE 53	TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	142
TABLE 54	NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	142
TABLE 55	EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	143
TABLE 56	ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	143
TABLE 57	LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	144
6.7	VIRAL VECTOR VACCINES	144
6.7.1	RISING INVESTMENT IN VACCINE DEVELOPMENT TO DRIVE MARKET	144
TABLE 58	VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	145
TABLE 59	NORTH AMERICA: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	145
TABLE 60	EUROPE: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	146
TABLE 61	ASIA PACIFIC: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	146
TABLE 62	LATIN AMERICA: VIRAL VECTOR VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	147
6.8	MRNA VACCINES	147
6.8.1	INCREASING FOCUS ON MRNA VACCINE DEVELOPMENT TO DRIVE MARKET	147
TABLE 63	MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	148

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 64	NORTH AMERICA: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	149
TABLE 65	EUROPE: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	149
TABLE 66	ASIA PACIFIC: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	150
TABLE 67	LATIN AMERICA: MRNA VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	150
6.9	OTHER VACCINES	151
TABLE 68	OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	151
TABLE 69	NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	152
TABLE 70	EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	152
TABLE 71	ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	153
TABLE 72	LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	153
7	VACCINES MARKET, BY TYPE	154
7.1	INTRODUCTION	155
TABLE 73	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)	155
TABLE 74	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION)	156
7.2	MULTIVALENT VACCINES	156
7.2.1	INCREASED NEED FOR IMMUNIZATION AND COST-EFFECTIVENESS TO DRIVE MARKET	156
TABLE 75	EXAMPLES OF MULTIVALENT VACCINES	157
TABLE 76	MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	158
TABLE 77	NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	158
TABLE 78	EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	159
TABLE 79	ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	159
TABLE 80	LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	160
7.3	MONOVALENT VACCINES	160
7.3.1	RIISING R&D INVESTMENTS AND PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH	160
TABLE 81	EXAMPLES OF MONOVALENT VACCINES	161
TABLE 82	MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	162
TABLE 83	NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	162
TABLE 84	EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	163
TABLE 85	ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	163
TABLE 86	LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	164
8	VACCINES MARKET, BY DISEASE INDICATION	165
8.1	INTRODUCTION	166
TABLE 87	VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)	166
TABLE 88	VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION)	167
8.2	PNEUMOCOCCAL DISEASE	167

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.2.1 INCREASING INCIDENCE OF PNEUMONIA IN CHILDREN TO DRIVE MARKET 167

TABLE 89 LIST OF COMMERCIALY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 168

TABLE 90 PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 169

TABLE 91 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 169

TABLE 92 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 170

TABLE 93 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 170

TABLE 94 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 171

8.3 INFLUENZA 171

8.3.1 RISING NEED FOR IMMUNIZATION AGAINST VIRAL INFECTIONS TO DRIVE MARKET 171

TABLE 95 LIST OF COMMERCIALY AVAILABLE INFLUENZA VACCINES 172

TABLE 96 INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 173

TABLE 97 NORTH AMERICA: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 173

TABLE 98 EUROPE: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 174

TABLE 99 ASIA PACIFIC: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 174

TABLE 100 LATIN AMERICA: INFLUENZA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 175

8.4 COMBINATION VACCINES 175

8.4.1 GROWING DEMAND FOR ALL-IN-ONE VACCINE TO DRIVE MARKET 175

TABLE 101 LIST OF COMMERCIALY AVAILABLE COMBINATION VACCINES 176

TABLE 102 COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 177

TABLE 103 NORTH AMERICA: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 177

TABLE 104 EUROPE: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 178

TABLE 105 ASIA PACIFIC: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 178

TABLE 106 LATIN AMERICA: COMBINATION VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 179

8.5 HPV 179

8.5.1 GROWING INCIDENCE OF SEXUALLY TRANSMITTED DISEASES TO DRIVE MARKET 179

TABLE 107 LIST OF COMMERCIALY AVAILABLE HPV VACCINES 180

TABLE 108 HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 181

TABLE 109 NORTH AMERICA: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 181

TABLE 110 EUROPE: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 182

TABLE 111 ASIA PACIFIC: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 182

TABLE 112 LATIN AMERICA: HPV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 183

8.6 MENINGOCOCCAL DISEASE 183

8.6.1 INCREASING INITIATIVES BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS TO DRIVE MARKET 183

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 113	LIST OF COMMERCIALY AVAILABLE MENINGOCOCCAL DISEASE VACCINES	184
TABLE 114	MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	184
TABLE 115	NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	185
TABLE 116	EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	185
TABLE 117	ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	186
TABLE 118	LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	186
8.7	HERPES ZOSTER	187
8.7.1	INCREASING INVESTMENT IN NOVEL VACCINE DEVELOPMENT TO DRIVE MARKET	187
TABLE 119	HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	188
TABLE 120	NORTH AMERICA: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	188
TABLE 121	EUROPE: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	189
TABLE 122	ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	189
TABLE 123	LATIN AMERICA: HERPES ZOSTER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	190
8.8	ROTAVIRUS	190
8.8.1	GROWING FOCUS OF GOVERNMENT AND NON-GOVERNMENT BODIES ON ROTAVIRUS PREVENTION TO PROPEL MARKET	190
TABLE 124	LIST OF COMMERCIALY AVAILABLE ROTAVIRUS VACCINES	191
TABLE 125	ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	191
TABLE 126	NORTH AMERICA: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	192
TABLE 127	EUROPE: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	192
TABLE 128	ASIA PACIFIC: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	193
TABLE 129	LATIN AMERICA: ROTAVIRUS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	193
8.9	MMR	194
8.9.1	RISING INCIDENCE OF MEASLES, MUMPS, AND RUBELLA TO BOOST DEMAND	194
TABLE 130	LIST OF COMMERCIALY AVAILABLE MMR VACCINES	194
TABLE 131	MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	195
TABLE 132	NORTH AMERICA: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	195
TABLE 133	EUROPE: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	196
TABLE 134	ASIA PACIFIC: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	196
TABLE 135	LATIN AMERICA: MMR VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	197
8.10	VARICELLA	197
8.10.1	INCREASING PROMOTION OF IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH	197
TABLE 136	LIST OF COMMERCIALY AVAILABLE VARICELLA VACCINES	197

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 137	VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	198
TABLE 138	NORTH AMERICA: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	198
TABLE 139	EUROPE: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	199
TABLE 140	ASIA PACIFIC: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	199
TABLE 141	LATIN AMERICA: VARICELLA VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	200
8.11	HEPATITIS	200
8.11.1	LOW SOCIO-ECONOMIC STANDARDS OF LIVING AND HIGH CONTAMINATION IN DRINKING WATER TO DRIVE MARKET	200
TABLE 142	LIST OF COMMERCIALY AVAILABLE HEPATITIS VACCINES	201
TABLE 143	HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	201
TABLE 144	NORTH AMERICA: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	202
TABLE 145	EUROPE: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	202
TABLE 146	ASIA PACIFIC: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	203
TABLE 147	LATIN AMERICA: HEPATITIS VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	203
8.12	DTP	204
8.12.1	INCREASED OCCURRENCE OF DIPHTHERIA, TETANUS, AND PERTUSSIS IN EMERGING ECONOMIES TO DRIVE MARKET	204
TABLE 148	LIST OF COMMERCIALY AVAILABLE DTP VACCINES	204
TABLE 149	DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	205
TABLE 150	NORTH AMERICA: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	205
TABLE 151	EUROPE: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	206
TABLE 152	ASIA PACIFIC: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	206
TABLE 153	LATIN AMERICA: DTP VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	207
8.13	POLIO	207
8.13.1	INCREASING GOVERNMENT INITIATIVES AND IMMUNIZATION PROGRAMS TO DRIVE MARKET	207
TABLE 154	POLIO VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	208
TABLE 155	NORTH AMERICA: POLIO VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	209
TABLE 156	EUROPE: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	209
TABLE 157	ASIA PACIFIC: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	210
TABLE 158	LATIN AMERICA: POLIO VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	210
8.14	RSV	211
8.14.1	STRONG PRODUCT PIPELINE AND NEW PRODUCT LAUNCHES TO PROPEL MARKET GROWTH	211
TABLE 159	RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION)	212
TABLE 160	NORTH AMERICA: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	212
TABLE 161	EUROPE: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	213
TABLE 162	ASIA PACIFIC: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	213
TABLE 163	LATIN AMERICA: RSV VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION)	214

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.15 OTHER DISEASE INDICATIONS 214

FIGURE 37 US: NUMBER OF COVID-19 CASES, 2020-2023 215

TABLE 164 LIST OF COMMERCIALY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 215

TABLE 165 VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 216

TABLE 166 VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 216

TABLE 167 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 217

TABLE 168 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 217

TABLE 169 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 218

TABLE 170 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 218

TABLE 171 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 219

TABLE 172 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 219

TABLE 173 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (INCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 220

TABLE 174 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 220

9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION 221

9.1 INTRODUCTION 222

TABLE 175 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), 2022-2029 (USD MILLION) 222

TABLE 176 VACCINES MARKET, BY ROUTE OF ADMINISTRATION (INCLUDING COVID-19 VACCINES), 2022-2029 (USD MILLION) 223

9.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 223

9.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION 223

TABLE 177 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 224

TABLE 178 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 225

TABLE 179 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 225

TABLE 180 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 226

TABLE 181 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 226

TABLE 182 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 227

9.3 ORAL ADMINISTRATION 227

9.3.1 REDUCED RISK OF BLOOD-TRANSMITTED INFECTIONS TO DRIVE ADOPTION 227

TABLE 183 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 228

TABLE 184 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 228

TABLE 185 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION) 229

TABLE 186 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 229

TABLE 187 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 230

9.4 OTHER ROUTES OF ADMINISTRATION 230

TABLE 188 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 231

TABLE 189 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 231

TABLE 190 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 232

TABLE 191 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 232

TABLE 192 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 233

10 VACCINES MARKET, BY END USER 234

10.1 INTRODUCTION 235

TABLE 193 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION) 235

TABLE 194 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION) 235

10.2 ADULT VACCINES 236

10.2.1 ADULT VACCINES TO COMMAND LARGER MARKET SHARE 236

TABLE 195 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 237

TABLE 196 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 237

TABLE 197 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 238

TABLE 198 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 238

TABLE 199 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 239

10.3 PEDIATRIC VACCINES 239

10.3.1 SUPPORT FROM GOVERNMENT AND NON-GOVERNMENT BODIES TO DRIVE MARKET 239

TABLE 200 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 240

TABLE 201 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 240

TABLE 202 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 241

TABLE 203 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 241

TABLE 204 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 242

11 VACCINES MARKET, BY REGION 243

11.1 INTRODUCTION 244

TABLE 205 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 244

TABLE 206 VACCINES MARKET (INCLUDING COVID-19 VACCINES), BY REGION, 2022-2029 (USD MILLION) 245

11.2 NORTH AMERICA 245

11.2.1 NORTH AMERICA: RECESSION IMPACT 245

FIGURE 38 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 246

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 207 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2022-2029 (USD MILLION) 247

TABLE 208 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION) 247

TABLE 209 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION) 248

TABLE 210 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION) 249

TABLE 211 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 250

TABLE 212 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION) 250

11.2.2 US 251

11.2.2.1 US to dominate North American market 251

TABLE 213 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2022-2029 (USD MILLION) 252

TABLE 214 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2022-2029 (USD MILLION) 252

TABLE 215 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2022-2029 (USD MILLION) 253

TABLE 216 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 254

TABLE 217 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2022-2029 (USD MILLION) 254

Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Global Forecast to 2029

Market Report | 2024-04-24 | 402 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	2025-05-19
		Signature	<div></div>